Zasocitinib (Next-Gen TYK2) LATITUDE Phase 3: Week 16 sPGA 0/1 ~70% — A Once-Daily Oral Could Reset Plaque Psoriasis Treatment
SCIENCE

Zasocitinib (Next-Gen TYK2) LATITUDE Phase 3: Week 16 sPGA 0/1 ~70% — A Once-Daily Oral Could Reset Plaque Psoriasis Treatment

By Léa · · AAD 2026 Late-Breaking
KO | EN

Takeda’s next-generation selective oral TYK2 inhibitor zasocitinib (TAK-279) achieved approximately 70% sPGA 0/1 (clear or almost clear) at week 16 in the Phase 3 LATITUDE-1 and LATITUDE-2 trials in moderate-to-severe plaque psoriasis. PASI 90 over 50%, PASI 100 around 30%, rapid response onset by week 4, and 90%+ response maintenance through week 60. After AAD 2026 late-breaking presentation, Takeda confirmed FDA NDA filing for fiscal 2026. A once-daily oral pill with biologic-level efficacy.

The Data

LATITUDE-1 (n=693) and LATITUDE-2 (n=1,108) evaluated zasocitinib in moderate-to-severe plaque psoriasis adults. Co-primary endpoints: week 16 sPGA 0/1 and PASI 75. Secondaries: PASI 90/100, time to response, week 60 maintenance.

Key results:

  • sPGA 0/1: ~70% (placebo 5-10%)
  • PASI 90: 50%+ at week 16 (placebo 4-8%)
  • PASI 100 (complete clearance): ~30% at week 16
  • Rapid onset: significant PASI 75 vs placebo by week 4
  • 24-week cumulative: response continues to deepen
  • 60-week maintenance: 90%+ of week 40 responders maintained
  • Safety: consistent with Phase 2b. No new signals. Common AEs: upper respiratory infection, acneiform eruption

Phase 2b efficacy reproduced more strongly in Phase 3. Takeda formalized FDA NDA filing plans for fiscal 2026 (April 2026 - March 2027).

Why TYK2 Differs from Other JAK Inhibitors

Among the JAK family, TYK2 mediates IL-12 and IL-23 signaling. The IL-23 → TYK2 → STAT3 → IL-17 axis is the molecular core of plaque psoriasis.

Existing JAK inhibitors (tofacitinib, baricitinib, upadacitinib) deliver broad JAK1/JAK2/JAK3 blockade — powerful but with broad side effects (anemia, neutropenia, MACE signal, infection risk).

Zasocitinib is TYK2-selective. Minimal effect on JAK1/2/3 means only IL-12/IL-23 signaling is blocked while other immune functions remain intact. Compared to deucravacitinib (FDA-approved 2022, the first TYK2 inhibitor), the next-generation zasocitinib offers stronger TYK2 selectivity and higher efficacy.

Limits of Current Plaque Psoriasis Treatment

  • Topical corticosteroids: mild disease, area-limited
  • Phototherapy (NB-UVB): time burden, access constraints
  • Methotrexate, cyclosporine: immunosuppression + long-term toxicity
  • Biologics (TNF-α, IL-17, IL-23 inhibitors): powerful but injectable + cost + immunogenicity
  • Deucravacitinib (Sotyktu, 2022): first oral TYK2. ~50% PASI 75 at week 16

Zasocitinib’s impact:

  • Oral once-daily, not injected
  • Biologic-comparable efficacy
  • Superior side effect profile (TYK2-selective)
  • Sustained response (60-week 90%+)
  • Likely lower cost than biologics

What “PASI 100 of 30%” Means

Existing biologic week-16 PASI 100 rates:

  • Secukinumab (IL-17): ~28%
  • Ixekizumab (IL-17): ~39%
  • Risankizumab (IL-23): ~36%
  • Deucravacitinib (TYK2 1st gen): ~14%
  • Zasocitinib (TYK2 next gen): ~30%

Zasocitinib’s ~30% PASI 100 is essentially equivalent to IL-17/IL-23 biologics. Biologic efficacy in oral form is the key impact.

Clinical Application

  • Likely indication: 18+ moderate-to-severe plaque psoriasis (PASI 12+, BSA 10%+)
  • Dose: once-daily oral (exact dose pending labeling)
  • Time to effect: week 4 first response, week 16 primary, weeks 24-60 cumulative deepening
  • Monitoring: liver function, lipids, blood counts, TB and hepatitis B screening
  • Contraindications: active TB, hepatitis B, pregnancy
  • Side effects: upper respiratory infection, acneiform eruption, herpes reactivation. No MACE signal observed
  • Patient selection: phototherapy non-responders, injection-averse patients, biologic-naive
  • Combinations: topical corticosteroids OK; not co-administered with biologics
  • Pregnancy planning: effective contraception required; 6-month washout suggested